Auriga Reiterates Buy on MedAssets (MDAS)

By admin | 7 years ago

MedAssets (NASDAQ: MDAS)‘s stock had its “buy” rating restated by equities researchers at Auriga in a report issued on Thursday.

Shares of MedAssets traded down 2.82% during mid-day trading on Thursday, hitting $12.75. MedAssets has a 52 week low of $8.52 and a 52 week high of $16.28. The company has a market cap of $743.6 million and a P/E ratio of 2186.67.

The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.24 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.18 EPS by $0.06. The company’s quarterly revenue was up 14.9% on a year-over-year basis. On average, analysts predict that MedAssets will post $0.29 earnings per share next quarter.

A number of other firms have also recently commented on MDAS. Analysts at Caris & Co. downgraded shares of MedAssets from an “above average” rating to an “average” rating in a research note to investors on Monday, February 27th. Separately, analysts at UBS AG (NYSE: UBS) reiterated a “neutral” rating on shares of MedAssets in a research note to investors on Friday, February 24th. Finally, analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of MedAssets to $13.50 in a research note to investors on Friday, February 24th.

MedAssets, Inc. provides technology-enabled products and services. These solutions are designed to improve operating margin and cash flow for hospitals and health systems.

About the author